LILRB2 and non-small cell lung carcinoma: Moreover, in order to provide more clues about whether membrane or intracellular ILT4 played a role in NSCLC development, we used the anti-ILT4 blocking antibody treatment in NSCLC cells and found blocking ILT4 could slightly inhibit the aggressive phenotype in NSCLC cells, but not change the expressional level of VEGF-C (Supplementary Figure 8).